Tag: ACVR1C
-
Roche Licenses Rona’s ALK7 RNAi Candidate for Obesity
Roche licensed Rona’s ALK7 RNAi candidate for obesity in a potential $1.16 billion deal. The approach targets fat-cell biology, with clinical benefits pending.
Roche licensed Rona’s ALK7 RNAi candidate for obesity in a potential $1.16 billion deal. The approach targets fat-cell biology, with clinical benefits pending.